UB Paderborn / Katalog / Suche / in CDI

1 – 17 von 17

Sortiert nach

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

The New England journal of medicine, 2015-07, Vol.373 (2), p.123-135

2015

Link zum Volltext

Verfügbarkeit prüfen

Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study

The lancet oncology, 2018-11, Vol.19 (11), p.1468-1479

2018

Link zum Volltext

Verfügbarkeit prüfen

Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial

The lancet oncology, 2019-10, Vol.20 (10), p.1370-1385

2019

Link zum Volltext

Verfügbarkeit prüfen

Cabozantinib, a New Standard of Care for Patients With Advanced Renal Cell Carcinoma and Bone Metastases? Subgroup Analysis of the METEOR Trial

Journal of clinical oncology, 2018-03, Vol.36 (8), p.765-772

2018

Link zum Volltext

Verfügbarkeit prüfen

Blood First Assay Screening Trial (BFAST) in Treatment-Naive Advanced or Metastatic NSCLC: Initial Results of the Phase 2 ALK-Positive Cohort

Journal of thoracic oncology, 2021-12, Vol.16 (12), p.2040-2050

2021

Link zum Volltext

Verfügbarkeit prüfen

Avelumab Versus Docetaxel in Patients With Platinum-Treated Advanced NSCLC: 2-Year Follow-Up From the JAVELIN Lung 200 Phase 3 Trial

Journal of thoracic oncology, 2021-08, Vol.16 (8), p.1369-1378

2021

Link zum Volltext

Verfügbarkeit prüfen

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

The New England journal of medicine, 2018-04, Vol.378 (14), p.1277-1290

2018

Link zum Volltext

Verfügbarkeit prüfen

Thirty-month follow-up of the phase III CheckMate 214 trial of first-line nivolumab + ipilimumab (N+I) or sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC)

Journal of clinical oncology, 2019-03, Vol.37 (7_suppl), p.547-547

2019

Link zum Volltext

Verfügbarkeit prüfen

Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised phase 3 trial

The lancet oncology, 2019-08, Vol.20 (10), p.1370-1385

2019

Link zum Volltext

Verfügbarkeit prüfen

Concordance Analysis of ALK Gene Fusion Detection Methods in Patients with Non–Small-Cell Lung Cancer from Chile, Brazil, and Peru

The Journal of molecular diagnostics : JMD, 2021-09, Vol.23 (9), p.1127-1137

2021

Link zum Volltext

Verfügbarkeit prüfen

1 – 17 von 17

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(16)
Mit Volltextzugriff
(17)

Publikationsform

Artikel
(17)

Sprache

Englisch
(16)
Japanisch
(3)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(14)
Science & Technology
(14)
Humans
(11)
Oncology
(11)
Male
(8)
Aged
(7)
Female
(7)
Immunotherapy
(7)
Middle Aged
(7)
Monoclonal Antibodies
(7)
Patients
(7)
Targeted Cancer Therapy
(6)
Adult
(5)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(5)
Lung Cancer
(5)
Lung Neoplasms - Drug Therapy
(5)
Metastasis
(5)
Aged, 80 And Over
(4)
Carcinoma, Non-Small-Cell Lung - Mortality
(4)
Lung Neoplasms - Mortality
(4)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

Molecular Epidemiology of ALK Rearrangements in Advanced Lung Adenocarcinoma in Latin America

Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study

Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial

Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer

Cabozantinib, a New Standard of Care for Patients With Advanced Renal Cell Carcinoma and Bone Metastases? Subgroup Analysis of the METEOR Trial

Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial

First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817

Blood First Assay Screening Trial (BFAST) in Treatment-Naive Advanced or Metastatic NSCLC: Initial Results of the Phase 2 ALK-Positive Cohort

Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma

Avelumab Versus Docetaxel in Patients With Platinum-Treated Advanced NSCLC: 2-Year Follow-Up From the JAVELIN Lung 200 Phase 3 Trial

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

Thirty-month follow-up of the phase III CheckMate 214 trial of first-line nivolumab + ipilimumab (N+I) or sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC)

Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised phase 3 trial

Concordance Analysis of ALK Gene Fusion Detection Methods in Patients with Non–Small-Cell Lung Cancer from Chile, Brazil, and Peru

EN-2. CheckMate 017 / 057 5-year survival outcomes : NIVO vs Docetaxel in Previously Treated Advanced NSCLC

Suchergebnisse filtern